Recce Pharmaceuticals (ASX:RCE) completed the dosing of 30 patients for a phase two trial investigating the use of the Recce 327 topical gel in patients with acute bacterial skin and skin structure infections, according to a Tuesday filing with the Australian bourse.
The open-label study aims to assess the safety and tolerability, plasma pharmacokinetics, and efficacy of the topical gel following daily application for seven to 14 days, the filing said.
Results from the study are anticipated within the first quarter, per the filing.
Shares of the pharmaceutical firm rose past 2% in recent Tuesday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。